In a strategic move to expand its global footprint, Scilex Holding Company has entered into a Master Distributor Agreement with CH Trading Group and Devart Middle East. This agreement aims to distribute ZTlido®, a non-opioid pain management product, across Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa. The collaboration is expected to enhance the availability of ZTlido® in these regions, providing patients with an effective solution for neuropathic pain associated with post-herpetic neuralgia (PHN).
Scilex Holding Company, known for its innovative non-opioid pain management products, has taken a significant step towards global expansion. The Master Distributor Agreement with CH Trading Group and Devart Middle East will facilitate the distribution of ZTlido® in six key markets. This partnership is part of Scilex’s broader strategy to increase its presence in the Middle East and North/South Africa regions. By leveraging the expertise and networks of CH Trading Group and Devart Middle East, Scilex aims to reach a larger patient population.
The agreement designates Devart Middle East as the Master Distributor, responsible for promoting, marketing, selling, and distributing ZTlido® in the designated territories. CH Trading Group will act as the Territories Distributor, continuing its efforts to expand the commercialization of ZTlido® in the Middle East and North/South Africa markets. This collaboration is expected to drive significant growth for Scilex and improve access to effective pain management solutions for patients in these regions.
Benefits of ZTlido®
ZTlido® is a lidocaine topical system designed to provide continuous pain relief for up to 12 hours. It addresses the limitations of traditional prescription lidocaine patches by offering improved adhesion and sustained efficacy. Since its launch, over one million patients in the United States have been treated with ZTlido®, making it the number one prescribed non-opioid branded pain medication by pain specialists. The product’s success in the US market highlights its potential to benefit patients in the newly designated territories.
The effectiveness of ZTlido® in managing neuropathic pain associated with PHN has been well-documented. Patients report high satisfaction rates, with 89% of users in a recent survey expressing complete or mostly satisfaction with the treatment. The introduction of ZTlido® in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa is expected to provide a much-needed alternative for patients suffering from chronic pain. This expansion aligns with Scilex’s mission to offer non-opioid pain management solutions globally.
Strategic Implications
The Master Distributor Agreement marks a significant milestone for Scilex Holding Company. By partnering with CH Trading Group and Devart Middle East, Scilex is poised to enhance its market presence and drive growth in key regions. This collaboration not only expands the reach of ZTlido® but also sets the stage for the potential distribution of other products in Scilex’s non-opioid pain portfolio. The agreement underscores Scilex’s commitment to addressing the global need for effective pain management solutions.
The strategic implications of this partnership extend beyond the immediate distribution of ZTlido®. It opens the door for further collaborations and market expansions, positioning Scilex as a leading player in the non-opioid pain management sector. The successful implementation of this agreement will likely pave the way for similar initiatives in other regions, further solidifying Scilex’s global footprint. As the company continues to innovate and expand, it remains dedicated to improving the quality of life for patients worldwide.
